Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
Price : $35 *
At a glance
- Drugs Aprepitant (Primary) ; Lurbinectedin (Primary) ; Cisplatin
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors PharmaMar
- 25 Jan 2017 Status changed from recruiting to completed.
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
- 05 Oct 2016 According to a PharmaMar media release, data from this study will be presented at European Society of Medical Oncology (ESMO) congress 2016